Click here for Bosulif®▼ (bosutinib monohydrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Please use the links below to access the Bosulif clinical papers
Cortes JE et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology 2018; 36(3): 231-7
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-BOS-GBR-0970. March 2020
BOSULIF is indicated for the treatment of adult patients with:
Newly-diagnosed chronic phase (CP) Philadelphia chromosomepositive chronic myelogenous leukaemia (Ph+ CML)
CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options
Newly-diagnosed CP Ph+ CML: The recommended dose is 400 mg bosutinib once daily.
CP, AP, or BP Ph+ CML with resistance or intolerance to prior therapy: The recommended dose is 500 mg bosutinib once daily.
In clinical trials for both indications, treatment with bosutinib continued until disease progression or intolerance to therapy.
Understand the differences between the 2013 and 2020 Guidelines
BOSULIF (bosutinib) is approved as an option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults, when:
Statement from Scottish Medicines Consortium website on Bosulif
Following a re-submission considered under the ultra-orphan medicine process1:
Bosutinib (Bosulif) is accepted for use within NHS Scotland.
Indication under review: Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Major cytogenetic response was achieved in 23/52 patients who represented “unmet medical need” within a non-comparative phase I/II study, in which the full population included 546 patients with CP, AP or BP imatinib pre-treated Ph+ CML.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of bosutinib. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020